scholarly journals Integrated approach in the treatment of metabolic syndrome

2014 ◽  
Vol 11 (1) ◽  
pp. 32-37 ◽  
Author(s):  
V A Uchamprina ◽  
T I Romantsova ◽  
M F Kalashnikova
Keyword(s):  
Quality Of Life ◽  
Insulin Resistance ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Clinical Outcomes ◽  
Antihypertensive Therapy ◽  
Standard Therapy ◽  
Integrated Approach ◽  
Study Group

The Goal of this study was to investigate the efficacy of the integrated approach for the treatment of metabolic syndrome (MS) aiming to correct all of its components versus standard therapy using clinical outcomes (BMI, waist circumference, blood pressure, lipid levels), assessment of psychological status (Beck Depression Inventory), and quality of life (SF-36). Methods: A total of 60 patients with MS were included in the study. The study group (30 subjects mean age 41.0±11 years, women - 23 (76.7%), men - 7 (23.3%)) received the complex therapy of MS - pharmacotherapy of obesity (orlistat) and insulin resistance (metformin), lipid-lowering therapy (statins or fibrates), antihypertensive therapy. Control group (30 patients mean age 43.4±9.5 years, women - 26 (86.7%), men - 4 (13.3%)) was treated with statins or fibrates and received antihypertensive therapy when needed. At the inclusion in the study and after 6 months of therapy all patients underwent clinical and laboratory investigation, assessment of depression and quality of life. Results: We found a more significant reduction of all clinical outcomes (body weight, blood pressure, improvement in glucose and lipid metabolism), a significant decrease in the prevalence and severity of the depression, and an improvement in the quality of life in patients of study group compared with standard therapy. Conclusion: Complex treatment of the MS, including pharmacotherapy of obesity (orlistat, Xenical) and insulin resistance (metformin, Glucophage) is characterized by a greater clinical efficacy compared with standard therapy.

scholarly journals Clinical and economic analysis of the modern strategies for treating metabolic syndrome

2014 ◽  
Vol 17 (2) ◽  
pp. 116-125
Author(s):  
Marina Fedorovna Kalashnikova ◽  
Vera Uchamprina ◽  
Tatiana Ivanovna Romantsova ◽  
Andrey Nikolaevich Gerasimov
Keyword(s):  
Quality Of Life ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Economic Analysis ◽  
Study Groups ◽  
Lipid Lowering ◽  
Control Group ◽  
Study Group ◽  
The Mean

Objective. The objective of this study was to identify the ways to optimize therapy for metabolic syndrome through complex clinical and economic analysis. Methods. Sixty patients with metabolic syndrome were included in the study. The study group (30 subjects with the mean age of 41.0?11 years, 23 females (76.7%), 7 males (23.3%)) received pharmacotherapy for obesity (orlistat) and insulin resistance (metformin), lipid-lowering therapy and antihypertensive therapy, if needed. The control group (30 patients with the mean age of 43.4?9.5 years, 26 females (86.7%), 4 males (13.3%)) received lipid-lowering and antihypertensive therapy, if needed. All patients underwent clinical and laboratory examination, assessment of depression (Beck Depression Inventory) and evaluation of the quality of life using the SF-36 questionnaire at admission to the study and after 6 months of therapy. Complex clinical and economic analyses, including cost-effectiveness and cost-utility analyses and calculation of such indices as ?the incremental cost-effectiveness ratio? (ICER), LYG, QALY and ?net monetary benefit? (NMB), were conducted based on the results obtained. Results. Improvement of clinical and laboratory indicators and quality of life in the study group was more significant than that in the control group. The direct medical costs were 33,440.40 RUB for the study group and 18,878.50 RUB for the control group (for 6 months of therapy). The control group CER was 4,016.70, while the study group CER was 3,125.30; ICER was 2,430.90 RUB. LYG was equal to 0.7 and 2.3 years for the control and the study groups, respectively. The QALY measure for the control and study groups was 8.63 and 9.45, respectively. The weighted average total costs for the intended period of living was 498,745.00 RUB for the control group and 457,866.00 RUB for the study group. The control group CUR was 57,792.00 and 54,902.00 RUB/QALY without and with discounting, respectively, while in the study group they were 48,451.00 and 46,029.00 RUB/QALY, respectively. The NMB for the control group amounted to 10,790,910.00 and 10,815,840.00 RUB without and with discounting, respectively, while for the study group the values were 11,904,500.00 and 11,927,390.00 RUB. Conclusions. The results of clinical and economic analysis show that treatment of the metabolic syndrome, including pharmacotherapy of obesity and insulin resistance, should be prioritized over mere medical advisory and lifestyle modifications.

Abstract P634: The Influence Of Virtual Learning Environment On Therapy Adherence And On The White Coat Effect

Hypertension ◽  
2015 ◽  
Vol 66 (suppl_1) ◽  
Author(s):  
Isabela R Fistarol ◽  
Chao L Wen ◽  
Luiz Bortolotto ◽  
Margarida Vieira ◽  
Miriam Tsunemi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Educational Technology ◽  
Learning Environment ◽  
Statistical Difference ◽  
Virtual Learning Environment ◽  
White Coat ◽  
Study Group ◽  
White Coat Effect

Systemic arterial hypertension is a risk factor for cardiovascular diseases and has become a common public health problem. Health education associated with educational technology may be used to encourage patients’ adherence to treatment and enable them to adequately understand how harmful hypertension can be to health, thereby promoting their quality of life. OBJECTIVE: To evaluate the influence of a strategy in an individual orientation program using educational technology associated with virtual learning environment (VLE) of hypertension care on the reduction in the white coat effect and the improvement in blood pressure control to be promoted by a nurse in a hypertension unit in a government state hospital in São Paulo. METHODS AND MATERIALS:This was a randomized clinical education study conducted with two groups, the VLE group (study group, 10 patients) and the control group (16 patients). Both groups were interviewed 6 times by nurses during the 120-day follow-up at 20-day intervals. At baseline (randomization) and at the end of the study, the patients took Spielberg’s State-Trait Anxiety Inventory (STAI), the Morisky test, and the WHOQOL, a quality of life instrument, and had their blood pressure taken (ambulatory blood pressure monitoring [ABPM]). Both groups had their blood pressure, weight, and abdominal circumference measured. Only the study group had remote access to the VLE. This consisted of 6 specific educational modules, each released according to the encounter number. RESULTS: At baseline, there were no statistical differences between the two groups with respect to the sociodemographic and hemodynamic variables. At the end of the study, there was a significant statistical difference between the groups on the Morisky test (p=0.001) and on the WHOQOL with respect to domain 3 social (p=0.001). There was no statistical difference with respect to the white coat effect between the groups. Nor was there any statistical difference between the groups with respect to the association of the anxiety degree measured by STAI and the white coat effect.CONCLUSION: In light of the results, our strategy improved the quality of life in the social domain and changed the adherence behavior of the study group in relation to the forgetfulness of medication schedules.

scholarly journals Pengaruh Medication Therapy Management (MTM) terhadap Outcome Klinik dan Kualitas Hidup Pasien Hipertensi di Puskesmas Kota Yogyakarta

2021 ◽  
Vol 10 (4) ◽  
Author(s):  
Tiara Dewi Salindri Pratama ◽  
Nanang Munif Yasin ◽  
Susi Ari Kristina
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Clinical Outcomes ◽  
Medication Therapy Management ◽  
Wilcoxon Test ◽  
P Value ◽  
Hypertensive Patients ◽  
Therapy Management ◽  
Medication Therapy

Medication therapy management (MTM), is a service model aimed at helping general health problems by preventing morbidity and mortality. Hypertension is a non-communicable disease which is a serious health problem which requires long-term therapy.  This study aims to see the effect of MTM on clinical Outcomes and quality of life of patients in hypertensive patients. This type of research is a quasi experimental one group with a pretest-posttest design. Analysis using paired sample t-test and Wilcoxon test with a significance used P <0,05. Respondents were 70 people, 67,1% were women. The characteristics of the majority age are 55-64 years with a percentage of 51,4%, the majority of education level is high school with 42,8%, non-civil servant jobs with a percentage of 45,7%, the length of diagnosis is dominated by 1-10 years (77,1%) and comorbidities diabetes mellitus occurred the most (10,0%). The results showed that the quality of life increased from before getting MTM 54,4 ± 8,9 and after MTM intervention 60,4 ± 6,6 (P value <0,001). Clinical outcome from systolic 159,2 ± 8,9 mmHg and diastolic 103,8 ± 8,0 mmHg before MTM to 144,1 ± 14,4 mmHg for systolic and 89,7 ± 8,8 mmHg for diastolic with p value <0,001 (p <0,05) for systolic blood pressure and p value: 0,016 (p <0,05) after receiving MTM intervention. Medication Therapy Management (MTM) has a significant influence on improving the quality of life and clinical Outcomes of hypertensive patients. The higher the quality of life of patients, blood pressure becomes more controlled.

scholarly journals The Association of Quality of Life and Personality Characteristics with Adolescent Metabolic Syndrome: A Cohort Study

2020 ◽  
Author(s):  
xiaohua liang ◽  
Peng Zhang ◽  
Shunqing Luo ◽  
Guifang Zhang ◽  
Xian Tang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Cohort Study ◽  
Psychological Health ◽  
Protective Factor ◽  
Community Intervention ◽  
Density Lipoprotein ◽  
Personality Score

Abstract Background: Increased prevalence of adolescent metabolic syndrome (MS) is a tracking factor for adulthood cardiovascular diseases. This study aimed to explore the potential relationship of quality of life (QoL) and personality traits with adolescent MS. Methods：1961 participants aged 11.68 years from a cohort study established in 2014 and followed in 2019 was included in Chongqing. Quality of life (QoL) and Eysenck’s personality questionnaire and MS components were collected.Results：The prevalence of adolescent MS is 4.69% (95% confidence interval, 3.84%-5.72%). Higher QoL domain score of physical activity ability (PAA) was a protective factor for both MS and MS score (all P<0.01), which was mainly negatively correlated with central obesity, diastolic blood pressure (DBP) and triglycerides levels, and positively correlated with high density lipoprotein cholesterol (HDL-C) level. Total score of QoL was negatively correlated with triglycerides level and positively correlated with DBP (all P<0.01). High extraversion personality score was a protective factor of adolescent MS (P=0.04) and MS score (P=0.06), which was mainly negatively correlated WC systolic blood pressure and TGs, and positively correlated with HDL-C (all P≤0.01).Conclusions：QoL score and extraversion personality score were independent protective factors for both MS prevalence and MS score, suggesting the community intervention to improve the QoL and psychological health of children is essential.

scholarly journals A COMPENDIOUS REVIEW ON THE METABOLIC SYNDROME; ITS IMPACT ON THE QUALITY OF LIFE

2018 ◽  
Vol 11 ◽  
Author(s):  
Rajalakshimi V ◽  
Vijey Aanandhi M
Keyword(s):  
Quality Of Life ◽  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Sleep Disturbances ◽  
Pharmacological Therapy ◽  
Lifestyle Changes ◽  
Behavioral Strategies ◽  
Central Adiposity ◽  
The Metabolic Syndrome

Background: Metabolic syndrome (MetS), a comprehensive condition is universally described as a group of several causative factors or abnormalities directly linked with insulin resistance that obviously augment the threat mainly for coronary heart disease, diabetes mellitus Type 2, some types of cancers and sleep disturbances, etc. MetS is a contemporary condition that covers a wide-ranging display of disorders with definite metabolic anomalies demonstrating at different times. Consequently, the threat of MetS remains epidemic. This review will potentially study significant factors such as central adiposity, insulin resistance, hypertension, and dyslipidemia; increased inflammation, environmental factors, and genetic predisposition are involved in MetS development. Purpose: This review provides the available facts to validate the relationship between MetS and quality of life. Methods: A thorough exploration in many search engines such as PubMed, Medline, Science direct, EMBASE, and Google scholar was carried out to recognize qualified studies. Results: Almost all studies suggested that MetS is significantly associated with impair quality of life. Lifestyle intervention holds the early preference and such non-pharmacological therapy combines specific suggestion on diet and physical activity with behavioral strategies. For the individuals, where contributing factors are not sufficiently condensed with lifestyle changes, pharmacological treatment should be considered. Conclusion: Therefore, the current study reviews the outline of literature interrelated with the MetS’s characterization, epidemiological existence, pathological process, and management advance for all the risk factors encompassing metabolic disorder.

scholarly journals Effect of Adherence with Clinical Outcomes and Quality of Life Primary Hypertension Patients in Pharmacy

2020 ◽  
Vol 3 (2) ◽  
pp. 47-53
Author(s):  
Dumartina Hutauruk ◽  
Khairunnisa ◽  
Wiryanto
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Clinical Outcomes ◽  
Significant Relationship ◽  
Strong Correlation ◽  
Primary Hypertension ◽  
Moderate Correlation

This study aimed to examine the effect of adherence to clinical outcomes and the quality of life of primary hypertension patients in pharmacy. The studywas conducted cross sectionally involved 60 patients at one of the pharmacies in Medan, Indonesia. Adherence was obtained in the form of adherence levels measured using the MMAS-8 questionnaire, clinical outcomes assessed by measuring a patient's blood pressure, and quality of life assessed using the EQ-5D-3L questionnaire. Then the data were analyzed using the Spearmen rho test. Patients who participated in the study consisted of 24 men and 36 women. Almost patient has low adherence with blood pressure mean of 156/ 90 mmHg. The patient's quality of life was 77.7%. Adherence has a significant relationship to clinical outcomes (p<0.05) with a strong correlation of r= -0.745. Adherence has a relationship to quality of life (p<0.05) with moderate correlation r= 0.554. This study concluded that adherence has a correlation with clinical outcomes and the quality of life of primary hypertension patients.

scholarly journals Assessment of Biological Parameters that (Influence) Affect the Quality of Life in a Group of Patients with Metabolic Syndrome

2021 ◽  
Vol 26 (3) ◽  
pp. 18-23
Author(s):  
Ovidiu Boitor ◽  
Laura Ștef ◽  
Gabriela Boţa ◽  
Romeo Mihăilă
Keyword(s):  
Quality Of Life ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Age Groups ◽  
Hdl Cholesterol ◽  
Biological Data ◽  
Age Group ◽  
Low Hdl ◽  
The Impact

Abstract The study included a group of 42 patients with metabolic syndrome and 32 patients without metabolic syndrome. The following biological data: BMI, blood pressure, type 2 diabetes, low HDL cholesterol levels were statistically compared using the ANOVA test. To assess the impact on quality of life, patients in both groups completed the EQ-5D-3L questionnaire. To verify the statistical confirmation of the results we used the Chi 2 test. In order to correlate the results with the gender and age of the patients, we formed the following age groups 45-54 years, 55-64 years, 65-74 years and over 75 years. We found that the dimensions that affect the quality of life differ depending on the age group as follows: in the 55-64 age group pain / discomfort predominates p = 0.009 and in the 65-74 age group the mobility and self-care dimensions p = 0.043 predominate. We did not obtain statistical confirmation by the Chi 2 test in patients with metabolic syndrome and the variable blood pressure Chi 2 = 5.27 and p = 0.072

Sign in / Sign up

Export Citation Format

Share Document